Evrópusambandið - íslenska - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Æxlishemjandi lyf - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

paion deutschland gmbh - ace ii myndir - hypotension; shock - lyf sem hafa áhrif á renín-angíótensín kerfið - giapreza er ætlað fyrir meðferð svarar lágur blóðþrýstingur í fullorðnir með klósett eða öðrum distributive áfall sem áfram blóðþrýstingslækkandi þrátt fyrir fullnægjandi bindi endurheimt og umsókn katekólamína og öðrum í boði vasopressor meðferð.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - Önnur lyf í taugakerfinu - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - Æxlishemjandi lyf - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mergæxli - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

bayer ab* - levonorgestrelum inn; ethinylestradiolum inn - tafla

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

galderma nordic ab - ivermectinum inn - krem - 10 mg/g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

exeltis healthcare s.l. - levonorgestrelum inn; ethinylestradiolum inn - filmuhúðuð tafla - 0,15 mg/0,03 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

csl behring gmbh - manna eðlilegt immúnóglóbúlín (scig) - Ónæmisfræðilegir skortsyndar - Ónæmiskerfið sera og mótefni, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - incivo, ásamt sýnt alfa og sögu, er ætlað fyrir meðferð arfgerð-1 langvarandi lifrarbólgu c í fullorðinn sjúklinga með bætt lifrarsjúkdóm (þar á meðal skorpulifur):sem eru í meðferð barnaleg;sem hefur áður verið í meðferð með sjúklinga alfa (mjög eða ekki mjög) einn eða í bland með sögu, þar á meðal relapsers, að hluta svörun og núll svörun.